American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care
02 Octobre 2023 - 2:00PM
The American Society of Anesthesiologists (ASA) and Pacira
BioSciences, Inc. (Nasdaq: PCRX), today announced a new grant of
$2.5 million, by Pacira to the ASA Charitable Foundation, to
advance the medical specialty of anesthesiology and pain medicine;
facilitate best-in-class clinician education; and improve patient
care.
“ASA has long been driven by a commitment to advocacy for
patients, championing for the continued advancement of the field of
pain management in both acute and chronic settings,” said ASA
President Michael W. Champeau, M.D., FAAP, FASA. “We look forward
to the meaningful progress we can continue to make for our 56,000
members and the patients they serve, supported by this generous
grant from Pacira.
“Anesthesiologists are an essential ally in our mission to
provide long-lasting opioid-free pain relief to as many patients as
possible,” said Dave Stack, Chairman and Chief Executive Officer of
Pacira. “We are committed to working together, so that ASA and
Pacira can effectively advance our common goal of optimizing
patient outcomes. We look forward to a productive relationship with
ASA, and to supporting ASA in its dedication to raising and
maintaining the standards of the practice of anesthesiology.”
About the American Society of
Anesthesiologists
Founded in 1905, the American Society of Anesthesiologists (ASA)
is an educational, research, and scientific professional society
with more than 56,000 members organized to advance the medical
practice of anesthesiology and secure its future. ASA is committed
to ensuring anesthesiologists evaluate and supervise the medical
care of all patients before, during, and after surgery. ASA members
also lead the care of critically ill patients in intensive care
units, as well as treat pain in both acute and chronic
settings.
For more information on the field of anesthesiology, visit the
American Society of Anesthesiologists online at asahq.org. To learn
more about how physician anesthesiologists help ensure patient
safety, visit www.asahq.org/MadeforThisMoment. Like ASA on
Facebook, follow ASALifeline on Twitter.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) has three
commercial-stage products: EXPAREL® (bupivacaine liposome
injectable suspension), ZILRETTA® (triamcinolone acetonide
extended-release injectable suspension), and ioveraº®, a novel,
handheld device for delivering immediate, long-acting, drug-free
pain control using precise, controlled doses of cold temperature to
a targeted nerve. Pacira is also developing other innovative
products to address debilitating conditions such as cardiac
electrical storm, atrial fibrillation, chronic pain, and
spasticity. To learn more about Pacira, visit www.pacira.com.
Investor Contact:
Pacira:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com
Media Contact:
ASA:
Theresa Hill (773) 330-5273
t.hill@asahq.org
Pacira:
Amber Sears, (973) 254-3587
amber.sears@pacira.com
Pacira BioSciences (NASDAQ:PCRX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Pacira BioSciences (NASDAQ:PCRX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024